Targeted Gene Therapy with Nanoparticles for Eye Disease
Author Information
Author(s): Salehi-Had Hani, Roh Mi In, Giani Andrea, Hisatomi Toshio, Nakao Shintaro, Kim Ivana K., Gragoudas Evangelos S., Vavvas Demetrios, Guccione Samira, Miller Joan W.
Primary Institution: Massachusetts Eye and Ear Infirmary, Harvard Medical School
Hypothesis
Can a novel nanoparticle targeting integrin αvβ3 effectively image and treat choroidal neovascularization?
Conclusion
Targeted gene delivery with nanoparticles significantly reduces the size and leakage of choroidal neovascularization by inducing apoptosis.
Supporting Evidence
- GFP plasmid expression was observed in vivo for up to 3 days after nanoparticle injection.
- Treatment with NP-ATPμ-Raf led to a 42% reduction in CNV size.
- Significantly more apoptotic cells were found in treated CNV compared to controls.
- Fluorescein angiography showed less leakage in treated CNV.
Takeaway
Researchers used tiny particles to deliver medicine directly to bad blood vessels in the eye, helping to shrink them and reduce leaks.
Methodology
Rats were treated with nanoparticles carrying a gene to reduce blood vessel size after inducing choroidal neovascularization.
Potential Biases
Potential bias in the evaluation of treatment effects due to the lack of blinding in some assessments.
Limitations
The study was conducted on rats, and results may not directly translate to humans.
Participant Demographics
Brown-Norway male rats, weighing 175–225 grams.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website